Clinical Trial

Taldefgrobep Alfa in Adults With Overweight and Obesity

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2025-12-04; most recent amendment 2026-03-19.
Status change: Recruiting → Active, Not Recruiting 2026-03-19
Trial Details
NCT Number NCT07281495
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Obesity, Overweight
Enrollment 150 participants
Start Date 2025-11-24
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-20